Symbols

OSA(Delisted)

ProSomnus·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About OSA

Prosomnus, Inc.

A pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea

Industry

Established Date

Listing Date

07/28/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

136

Fiscal Year Ends

12-31

Website

prosomnus.com

Security Type

Common stock

Office address

5675 Gibraltar Drive, Pleasanton, CA 94588

Business

Introduction

ProSomnus, Inc., was incorporated in Delaware in March 2016. The company is a medical technology company focused on the development, manufacture and marketing of precision intraoral medical devices, a new option for the treatment and management of patients with mild to moderate obstructive sleep apnea (OSA). Each ProSomnus precision intraoral device is individually designed according to each patient's anatomy and treatment plan. The company's patented precision devices are designed to create unique, consistent and predictable biomechanical benefits that lead to effective, comfortable, economical and patient-preferred treatment outcomes for patients with OSA.

Company Financials

EPS

OSA has released its 2023 Q4 earnings. EPS was reported at -0.42, versus the expected -0.31, missing expectations. The chart below visualizes how OSA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

OSA has released its 2024 Q2 earnings report, with revenue of 9.09M, reflecting a YoY change of 31.12%, and net profit of -15.18M, showing a YoY change of -1777.46%. The Sankey diagram below clearly presents OSA's revenue sources and cost distribution.